NVS
Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 82.88$. Average daily volumn in 3 months 2.26M. Market cap 167.53B
Stock symbol : NVS. Exchange : NYSE. Currency : USD Lastest price : 76.57$. Total volume : 3.02M. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Novartis AG (NVS)
Last Price
76.57$Change
0.25Volume
3.02M
| Previous Close | 76.32 |
| Open | 76.45 |
| Day Range | 75.69-77.29 |
| Bid | 76.54 x 800 |
| Ask | 76.55 x 800 |
| Volume | 3.02M |
| Average Volume | 2.26M |
| Market Cap | 167.53B |
| Beta | 0.49 |
| 52 Week Range | 74.09-94.26 |
| Trailing P/E | 7.51 |
| Foward P/E | 11.50 |
| Dividend (Yield %) | 4.37% |
| Ex-Dividend Date | 2022-03-08 |
Financial Details
Organization
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form me... dicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Market Cap:
167.53BRevenue:
52.88BTotal Assets:
131.79BTotal Cash:
12.41B
News about "Novartis AG"
DAVENPORT & Co LLC Cuts Holdings in Novartis AG (NYSE:NVS)
Source from : Defense World - 1 days ago
DAVENPORT & Co LLC decreased its position in Novartis AG (NYSE:NVS – Get Rating) by 2.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor ...See details»
Novartis AG (NYSE:NVS) Shares Acquired by Global Retirement Partners LLC
Source from : Defense World - 2 days ago
Global Retirement Partners LLC boosted its position in Novartis AG (NYSE:NVS – Get Rating) by 4.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & ...See details»
Novartis to take U.S. drug patent case to Supreme Court
Source from : Reuters - 7 days ago
Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals ...See details»
Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands
Source from : Yahoo - 6 days ago
Novartis AG (NYSE: NVS) has revealed insights into the updated company strategy. The company said that a 'US-first' mindset, increasing the share of U.S. patients in clinical trials, and building ...See details»
Novartis AG: Diving Into the Drug Pricing Hit From the Inflation Reduction Act, We’ve Reduced Our FVEs by 2%
Source from : YAHOO!Finance - 10 days ago
Find the latest Novartis AG (NVS) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»
Novartis Planning to Bring Dispute Over Drug Patent to U.S. Supreme Court
Source from : AOL - 8 days ago
Investing.com -- Novartis AG (SIX:NOVN) says it plans to petition the U.S. Supreme Court to uphold the validity of its patent for a dosing regimen of its blockbuster multiple sclerosis drug ...See details»
Novartis to Petition US Supreme Court on Gilenya Patent
Source from : MarketWatch - 8 days ago
By Pierre Bertrand Novartis AG said Wednesday that it plans to file a petition with the U.S. Supreme Court to review the decision by a U.S. appeals ...See details»
Novartis Pharma AG: Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya (fingolimod) dosing regimen patent
Source from : Finanznachrichten - 8 days ago
and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»
Novartis unveils new focused strategy,...
Source from : Benzinga.com - 7 days ago
and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»
Novartis to FDA: No skinny labels for Entresto
Source from : BioWorld - 10 days ago
Claiming it would be impossible to carve out a so-called skinny label that would comply with generic drug “same labeling” rules, Novartis AG is petitioning the U.S. FDA, for the second time, not to ...See details»
Immunodeficiency Therapeutics Market to Surpass US$ 10,581.6 Million with a CAGR of 6.1% by 2028 | Abbott, Pfizer Inc., Novartis AG
Source from : Medgadget - 9 days ago
Key companies contributing to the global immunodeficiency therapeutics market include Bharat Serums and Vaccines Ltd., Bristol-Myers Squibb Company, Biocon, AstraZeneca, Abbott, Novartis AG ...See details»
Hemarthrosis Treatment Market Overview 2022 to 2030, Future Trends and Forecast | By -Novartis AG, Pfizer Inc, Sun Pharmaceuticals Ltd
Source from : MarketWatch - 8 days ago
The Global Hemarthrosis Treatment Market investigation report contains Types ( Operation Treatment, Medical Treatement ), Segmentation & all logical and factual briefs about the Market 2022 Overview, ...See details»
CAR-T Therapy Treatment Market Is Booming Worldwide TC BioPharm, Otsuka Pharmaceutical, Novartis AG
Source from : Digital Journal - 11 days ago
Some of the Top companies Influencing this Market include:TC BioPharm, Otsuka Pharmaceutical, Novartis AG, Adaptimmune, Gilead Sciences, Biocon, Ono Pharmaceutical, Gracell Biotechnology Ltd ...See details»
Muscle Spasticity Market: Adoption of Innovative Offerings To Boost Returns On Investment | Sun Pharmaceutical, Novartis AG, Merz Pharma
Source from : Medgadget - 8 days ago
Expanding dispatches of new medications and administrative endorsements for muscle spasticity drugs are supposed to drive development of the global muscle spasticity market over the forecasted ...See details»